Thienorphine
Thienorphine is a very potent, extremely long-acting, orally-active opioid analgesic with mixed agonist–antagonist properties which was developed by the Beijing Institute of Pharmacology and Toxicology as a potential treatment for opioid dependence. It is a high-affinity, balanced ligand of the μ-, δ-, and κ-opioid receptors, behaving as a partial agonist of the μ- and κ-opioid receptors and as an antagonist of the δ-opioid receptor. It also possesses relatively low affinity for the nociceptin receptor, where it acts as an antagonist. — Wikipedia
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Earliest trial started Aug 31, 2018 (NCT03656120)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Delta opioid receptorAGONIST
OPRD1 agonist
- Kappa opioid receptorAGONIST
OPRK1 agonist
- Mu opioid receptorPARTIAL AGONIST
OPRM partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaThienorphine ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03656120 | Phase 2 | Aug 31, 2018 | Beijing ziduhongye technology development co. LTD, Central South University, Huazhong University of Science and Technology, Jiao Tong University, People's Liberation Army of China, Sichuan University, University of Michigan |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing ziduhongye technology development co. LTD | Government | 1 | 0 | 1 | 2018 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2018 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Michigan | Academic/Hospital | 1 | 1 | 1 | 2018 |